Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Genetic Markers Associated With Response to Intravenous Ketamine

To see complete record on, please visit this link

Id: NCT04695405

Organisation Name: Brain and Cognition Discovery Foundation

Overal Status: Completed

Start Date: January 21, 2021

Last Update: August 18, 2021

Lead Sponsor: Brain and Cognition Discovery Foundation

Brief Summary: The Canadian Rapid Treatment Center of Excellence (CRTCE) is a healthcare facility principally focused on providing best practices of intravenous ketamine treatment to adult patients suffering from treatment resistant depression. Patients who have received IV ketamine at the clinic are eligible to participate in this study where genetic biomarkers are correlated with response to IV ketamine.

  • Treatment Resistant Depression

Total execution time in seconds: 0.62842297554016